The Effects of Inorganic Nitrate on Carbohydrate and Lipid Metabolism in Type 2 Diabetes: The Protocol of a Randomized Placebo-Controlled Clinical Trial
Abstract
Background and Aim: Decreased bioavailability of nitric oxide (NO) in type 2 diabetes contributes to disrupted pathways of glucose/insulin homeostasis and progression of long-term complications. Due to its ability to convert to NO, inorganic nitrate (NO3) has been recently highlighted as a potential therapeutic agent in type 2 diabetes.Materials and Methods: This research entails a double-blind, randomized, placebo-controlled, phase II clinical trial that will be conducted on 62 type 2 diabetic patients. The patients will be randomized to receive a 6-month daily dose of NO3-rich beetroot powder (5 g/d, contains ~250 mg NO3) or placebo (5 g/d, contains <25 mg NO3). The primary outcome is glycosylated hemoglobin A1c (HbA1c). The study is powered to detect a 0.75% reduction in HbA1c levels between the groups. Fasting serum glucose, serum insulin, lipid parameters, liver enzymes, thyroid function tests and complete blood count will be measured as secondary outcomes. The measurements will be done at baseline, and will be repeated in the fourth, twelfth and twenty-fourth weeks. Protocol of the study was approved by the ethical committee of the Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences (IR.SBMU.ENDOCRINE.REC.1395.322). The trial was registered in the Iranian Registry of Clinical Trials with the following identification: IRCT20180409039246N1.References
American Diabetes A. Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers. Clinical Diabetes : A Publication of the American Diabetes Association. 2017;35(1):5-26.
Ghasemi A, Zahediasl S. Is nitric oxide a hormone? Iran Biomed J. 2011;15(3):59-65.
Ghasemi A, Zahediasl S. Potential therapeutic effects of nitrate/nitrite and type 2 diabetes mellitus. Int J Endocrinol Metab. 2013;11(2):63-4.
Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294(1):F1-9.
Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5(2):88-97.
Masha A, Dinatale S, Allasia S, Martina V. Role of the decreased nitric oxide bioavailability in the vascular complications of diabetes mellitus. Curr Pharm Biotechnol. 2011;12(9):1354-63.
Bahadoran Z, Ghasemi A, Mirmiran P, Azizi F, Hadaegh F. Beneficial effects of inorganic nitrate/nitrite in type 2 diabetes and its complications. Nutr Metab (Lond). 2015;12:16.
Ghasemi A, Jeddi S. Anti-obesity and anti-diabetic effects of nitrate and nitrite. Nitric Oxide. 2017;70:9-24.
Affourtit C, Bailey SJ, Jones AM, Smallwood MJ, Winyard PG. On the mechanism by which dietary nitrate improves human skeletal muscle function. Front Physiol. 2015;6:211.
Aucouturier J, Boissiere J, Pawlak-Chaouch M, Cuvelier G, Gamelin FX. Effect of dietary nitrate supplementation on tolerance to supramaximal intensity intermittent exercise. Nitric Oxide. 2015;49:16-25.
Coles LT, Clifton PM. Effect of beetroot juice on lowering blood pressure in free-living, disease-free adults: a randomized, placebo-controlled trial. Nutrition Journal. 2012;11(1):106.
Bahadoran Z, Mirmiran P. The Nitrate-Independent Blood Pressure-Lowering Effect of Beetroot Juice: A Systematic Review and Meta-Analysis. 2017;8(6):830-8.
Bahadoran Z, Mirmiran P, Azizi F, Ghasemi A. Nitrate-rich dietary supplementation during pregnancy: The pros and cons. Pregnancy Hypertension. 2018;11:44-6.
Sealed Envelope Ltd. 2017. Simple randomisation service. [Online] Available from: https://www.sealedenvelope.com/simple-randomiser/v1/ [Accessed 4 Aug 2018].
Bahadoran Z, Mirmiran P, Jeddi S, Azizi F, Ghasemi A, Hadaegh F. Nitrate and nitrite content of vegetables, fruits, grains, legumes, dairy products, meats and processed meats. Journal of Food Composition and Analysis. 2016;51:93-105.
Miranda KM, Espey MG, Wink DA. A Rapid, Simple Spectrophotometric Method for Simultaneous Detection of Nitrate and Nitrite. Nitric Oxide. 2001;5(1):62-71.
Mills CE, Govoni V, Casagrande ML, Faconti L, Webb AJ, Cruickshank JK. Design and progress of a factorial trial testing the effect of spironolactone and inorganic nitrate on arterial function in people at risk of or with type 2 diabetes. Artery Research. 2015;12:48-53.
Rathod KS, Jones DA, Van-Eijl TJ, Tsang H, Warren H, Hamshere SM, et al. Randomised, double-blind, placebo-controlled study investigating the effects of inorganic nitrate on vascular function, platelet reactivity and restenosis in stable angina: protocol of the NITRATE-OCT study. BMJ open. 2016;6(12):e012728.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340.
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation. Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This work is licensed under a Creative Commons license (CC-BY). However, the license permits any user to read, copy, redistribute and and make derivative the material in any medium or format for any purpose, even commercially.
